Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | HTStec | Kinase Screening & Profiling Trends 2008

Kinase Screening & Profiling Trends 2008

HTStec's Kinase Screening & Profiling Trends 2008 report was published on 2 June 2008. This 56 page report summarizes the results of HTStec’s global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling carried out in May 2008. The objectives were to document current practices and preferences in kinase screening and profiling, and to understand future user requirements, particularly with respect to the need for outsourced services. The aim was to compile a reference document on kinase screening and profiling metrics, which could be directly compared relative to HTStec’s 2006 report. The report is based on 53 responses from 41 different companies/organizations.

Executive Summary

o This market report summarizes the results of HTStec's third industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling carried out in May 2008.

o The study was initiated by HTStec to meet the specific needs, interests and focus of the survey sponsors. The objective was to document current practices and preferences in kinase screening and profiling, and to understand future user requirements, particularly with respect to the need for outsourced services. The aim was to compile a reference document on kinase screening and profiling metrics, which could be directly compared relative to HTStec's 2006 report. Equal emphasis was given to soliciting opinion from Pharma and Biotech market segments in both North America and Europe. In addition some feedback from academic screening centers was also obtained.

o The survey looked at in house and outsourced kinase screening and profiling, as practiced today (2008) and predicted for the future (2010). Specifically the following were investigated: therapeutic areas using kinase assays; kinase panel profiling approach; preferred kinase profiling assay technology, technology supplier and outsourced fee-for-service providers; interest in binding assays; main criteria for selecting a service provider; what outsourced providers should implement to drive decision making; kinase panel profiling budgets; kinases as a % of R&D spend; supplier/provider market share for in house and outsourced profiling; number of full time equivalents (FTE's) required to enable/support in house kinase panel profiling operations; average cost per single data point of kinase profiling assays; number of data points generated per year; data breakdown between single vs. replicate testing and dose response curves; number of kinase primary screens and data points per screen; interest and requirements for outsourcing kinase primary screening; size of the kinase panels used, representation of disease-relevant and mutant kinases; outsourced panel offerings of greatest interest; types of mode of action studies undertaken; use of different tyrosine kinase assay conditions; use of different species variants of kinases; satisfaction with data generated; interest in some outsourcing services; features of a kinase platform of greatest interest to respondents; and where kinase service providers should prioritize going forward.

o The main questionnaire consisted of 33 multi-choice questions, focused mainly on assay and budget metrics, and 1 open-ended question. In addition, there were 7 questions related solely to survey demographics.

o The survey collected 53 responses (41 complete & 12 partial responses) from 41 different organizations.

o Responses were split geographically 51% North America, 47% Europe, and 2% Asia (excluding Japan).

o Survey respondents were drawn from persons or groups involved in kinase primary screening, kinase selectivity profiling and the outsourcing of kinase testing to fee-for-service providers.

o Respondents came from 22 Large Pharma; 19 Small/Medium Pharma & Biotech; and 12 University, Research Institute or Government Labs. The majority (89%) of survey respondents had a senior job role or position which was in descending order either: section/group leader; director; senior scientist/researcher; department head; principal investigator; lab manager; vice president; professor/assistant professor; and research associate.

o Survey respondents represented: 15 primary screening (HTS) labs; 12 labs with multiple drug discovery roles; 10 assay development labs; 5 hit-to-lead (lead optimization) labs; 4 compound profiling labs; 3 other labs; 2 life science research labs; and 2 therapeutic area (target identification/validation) labs.

o Survey results were expressed as an average of all survey respondents. In addition, the data was fully reanalyzed after sub-division into the following 5 survey groups: 1) Large Pharma; 2) Medium/Small Pharma & Biotech; 3) University, Research Institute & Government Lab; 4) Europe; and 5) North America.

o The majority of respondent's kinase assays were undertaken within the oncology therapeutic area.

o The preferred approach to kinase profiling was to use a combination of in house and outsourced panels for selected lead compounds, with 47% of all kinase profiling activities outsourced in 2008.

o TR-FRET (Time Resolved FRET e.g. LANCE, HTRF, TR-IMAP, Lanthascreen) was the preferred in house kinase panel profiling assay technology and CisBio was the preferred technology supplier.

o Radiometric filter (e.g. P33 incorporation) or we don't have a preferred assay technology and go with CRO's recommendation were the most used outsourced kinase panel profiling methods. Millipore was the preferred outsourced profiling supplier and also the most trusted fee-for-service supplier to provide rapid turnaround and reliable results. Invitrogen was the second choice for preferred supplier.

o The majority of respondents think that activity assays are preferable to binding assays.

o Breadth of kinase coverage was the key decision-making criteria in selecting an outsourced kinase profiling supplier and the aspect kinase service suppliers should implement to drive decision making.

o The median kinase panel profiling budget allocations in 2008 were $25K-$50K/lab in house and $50K-$100K/lab outsourced.

o Cisbio had greatest share (18%) of the in house profiling market (for reagents and kits).

o Millipore had greatest market share (30%) of the outsourced kinase profiling market (services).

o Spending on kinases (in house + outsourced) was estimated to be a median of 10% of R&D budgets.

o The median number of FTE's allocated to support in house kinase profiling in 2008 was 2.

o The median cost per single data point for kinase panel profiling undertaken in 2008 was $0.25-$0.5/DP in house versus $1-$2/DP outsourced.

o The median total number of single data points tested in 2008 for kinase panel profiling was 25K-50K in house versus 5K-10K outsourced. The majority of outsourced kinase profiling data points were duplicate or replicate point (% inhibition) tests (n>1).

o The median number of kinase primary screens undertaken in 2008 was 1-5, each with a median of 100K-250K data points/primary screen.

o Nearly all survey respondents perform primary screens on both cell-based and biochemical kinase targets, but currently <33% outsource only 1 in 5 of their primary screens to service providers.

o The median size of the kinase panels being used by respondents in 2008 was 11-25 kinases in house, versus 76-100 kinases outsourced.

o The median representation of disease-relevant kinases in these panels in 2008 was 1-10 kinases in house, versus 21-30 kinases outsourced. Respondents want all known disease-relevant mutant kinases to be represented in outsourced panels.

o The preferred kinase panel offered by an outsourced provider has a median size of 201-250 kinases. Respondents want most either to be able to create their own panels and or to be able to cherry-pick individual assays from available panels.

o ATP competition was ranked as the type of investigation most undertaken during in house mode of action studies. When assaying tyrosine kinases the majority of respondents vary their use of Mg/ATP or Mn/ATP.

o The majority of respondents use human variants of their target kinase(s) for both in house and outsourced screening.

o Only a very small minority of respondents are dissatisfied with the data quality generated by their current kinase screening methods.

o Respondents were interested in the following outsourced services: 1) profiling 10 to 100 compounds weekly/monthly against a panel of disease-relevant kinases (<50); 2) response curve (IC50s or Kd's) screens against 100s of human kinases, to learn as much as possible about drug candidate(s) at a cost of <$25K per compound; and 3) a panel of cellular assays for specific kinases that complemented available in vitro biochemical assays.

o Lower cost per data point was rated the feature of a kinase screening platform of greatest interest to respondents and where they thought service providers should to focus their future efforts.

o Respondent's feedback on the improvements they think are required and the unmet needs that exist today in kinase panel profiling and related services are documented.

o Several bottom-up models were developed to estimate the global market for kinase profiling and screening. The kinase profiling market was estimated to be $42Million for in house reagents and $62Million for outsourced services in 2008. The kinase primary screening reagent market was estimated to be $106Million in 2008. Estimates for 2010 were made and growth rates determined for 4 market segments: 1) Large Pharma; 2) Medium/Small Pharma & Biotech; 3) Europe; and 4) North America.

o Quite a number of differences between the survey groups were identified.

Format: PDF June 2008
Table of Comtents
Price: $2,475.00 / €1,654.29

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions